Who are Imjudo's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tremelimumab (treme), Nivolumab in combination with Ipilimumab, Neoadjuvant ipilimumab + nivolumab, tremelimumab (anti-CTLA4), APVO101, AK102.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tremelimumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Imjudo — Competitive Intelligence Brief

Imjudo (TREMELIMUMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CTLA-4-directed Blocking Antibody [EPC]. Area: Oncology.

marketed CTLA-4-directed Blocking Antibody [EPC] CTLA-4 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Imjudo (TREMELIMUMAB) — AstraZeneca. Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Imjudo TARGET	TREMELIMUMAB	AstraZeneca	marketed	CTLA-4-directed Blocking Antibody [EPC]	CTLA-4	2022-01-01
tremelimumab (treme)	tremelimumab (treme)	AstraZeneca	marketed	CTLA-4 inhibitor	CTLA-4
Nivolumab in combination with Ipilimumab	Nivolumab in combination with Ipilimumab	Bristol-Myers Squibb	marketed	Checkpoint inhibitor combination (PD-1 inhibitor + CTLA-4 inhibitor)	PD-1 and CTLA-4
Neoadjuvant ipilimumab + nivolumab	Neoadjuvant ipilimumab + nivolumab	The Netherlands Cancer Institute	phase 3	Immune checkpoint inhibitor combination	PD-1 and CTLA-4
tremelimumab (anti-CTLA4)	tremelimumab (anti-CTLA4)	AstraZeneca	phase 3	Anti-CTLA4 monoclonal antibody	CTLA-4
APVO101	APVO101	Medexus Pharma, Inc.	phase 3	Dual checkpoint inhibitor	PD-1 and CTLA-4
AK102	AK102	Akeso	phase 3	Bispecific checkpoint inhibitor	PD-1 and CTLA-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CTLA-4-directed Blocking Antibody [EPC] class)

· 1 drug in this class
ASTRAZENECA AB · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imjudo — Competitive Intelligence Brief. https://druglandscape.com/ci/tremelimumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab